BR0206512A - Composto, método de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de um composto, e, processo para preparar um composto. - Google Patents

Composto, método de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de um composto, e, processo para preparar um composto.

Info

Publication number
BR0206512A
BR0206512A BR0206512-6A BR0206512A BR0206512A BR 0206512 A BR0206512 A BR 0206512A BR 0206512 A BR0206512 A BR 0206512A BR 0206512 A BR0206512 A BR 0206512A
Authority
BR
Brazil
Prior art keywords
disorders
compound
treatment
dementia
depression
Prior art date
Application number
BR0206512-6A
Other languages
English (en)
Inventor
Marc Chapdelaine
Timothy Davenport
Markus Haeberlein
Carey Horchler
John Mccauley
Edward Pierson
Daniel Sohn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0103650A external-priority patent/SE0103650D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0206512A publication Critical patent/BR0206512A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, MéTODO DE TRATAMENTO DE UM SER HUMANO OU ANIMAL QUE SOFRE DE DEPRESSãO, ANSIEDADE GENERALIZADA, DISTúRBIOS DA ALIMENTAçãO, DEMêNCIA, DISTúRBIO DO P‰NICO, DISTúRBIOS DO SONO, DISTúRBIOS GASTROINTESTINAIS, DISTúRBIOS MOTORES, DISTúRBIOS ENDóCRINOS, VASOESPASMO E DISFUNçãO SEXUAL, USO DE UM COMPOSTO, E, PROCESSO PARA PREPARAR UM COMPOSTO". E aqui fornecido um composto tendo a fórmula (I) em que os ditos compostos são úteis para o tratamento de distúrbios psiquiátricos incluindo mas não limitado à depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do pânico e distúrbios do sono. Os compostos também podem ser úteis no tratamento de distúrbios gastrointestinais, regulagem cardiovascular, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual. Os compostos são antagonistas do 5HT~ 1B~ e 5HT~ 1D~.
BR0206512-6A 2001-01-16 2002-01-15 Composto, método de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de um composto, e, processo para preparar um composto. BR0206512A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26210701P 2001-01-16 2001-01-16
SE0103650A SE0103650D0 (sv) 2001-11-01 2001-11-01 Therapeutic heterocyclic compounds
PCT/SE2002/000068 WO2002055012A2 (en) 2001-01-16 2002-01-15 Therapeutic heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR0206512A true BR0206512A (pt) 2004-01-06

Family

ID=26655583

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206512-6A BR0206512A (pt) 2001-01-16 2002-01-15 Composto, método de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de um composto, e, processo para preparar um composto.

Country Status (15)

Country Link
US (4) US6812225B2 (pt)
EP (1) EP1353913A2 (pt)
JP (1) JP4280067B2 (pt)
KR (2) KR100864356B1 (pt)
CN (1) CN100509794C (pt)
AR (2) AR035733A1 (pt)
AU (1) AU2002217742B2 (pt)
BR (1) BR0206512A (pt)
CA (1) CA2434152A1 (pt)
IL (1) IL156595A0 (pt)
MX (1) MXPA03006250A (pt)
NO (1) NO20033203L (pt)
NZ (2) NZ535574A (pt)
SA (1) SA02220710B1 (pt)
WO (1) WO2002055012A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000001793A (ko) * 1998-06-13 2000-01-15 이경하 신규한 벤조피란 또는 티오벤조피란 유도체
MXPA03006250A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos heterociclicos terapeuticos.
SE0103646D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic chroman compounds
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
SE0103649D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
US6963002B2 (en) * 2003-07-04 2005-11-08 Glenmark Pharmaceuticals Limited Process for the preparation of 4,4-dimethyl-6-ethynylthiochroman
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
CN101120002A (zh) 2005-02-17 2008-02-06 惠氏公司 环烷基稠合的吲哚、苯并噻吩、苯并呋喃和茚衍生物
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CA2616473A1 (en) 2005-07-27 2007-03-08 F. Hoffmann-La Roche Ag 4-aryloxy quinoline derivatives as 5-ht6 modulators
UY29896A1 (es) * 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
UY29892A1 (es) * 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
WO2007053093A1 (en) * 2005-11-04 2007-05-10 Astrazeneca Ab Chroman compounds as 5 ht1b antagonists
AR059356A1 (es) * 2006-02-14 2008-03-26 Astrazeneca Ab Nuevos radioligandos
WO2007097697A1 (en) * 2006-02-23 2007-08-30 Astrazeneca Ab Therapeutic quinoline compounds that are 5ht1b modulators
WO2008142623A2 (en) * 2007-05-17 2008-11-27 Piramal Life Sciences Limited Tumor necrosis factor - alpha inhibitors
AU2008258560C1 (en) 2007-06-08 2014-04-10 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
WO2008148840A1 (en) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
PE20090362A1 (es) 2007-06-08 2009-04-04 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina como moduladores de dgat
NZ577415A (en) * 2008-06-04 2011-01-28 Resmed Ltd Breathing apparatus attached to the face using a hook and loop fastener having one side adhered to the skin
PE20140572A1 (es) 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
US20140182600A1 (en) * 2012-12-27 2014-07-03 3M Innovative Properties Company Filtering face-piece respirator having welded indicia hidden in pleat
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
AU2021342568B2 (en) 2020-09-21 2025-04-03 Landos Biopharma, Inc. Nlrx1 ligands
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1428186A (en) * 1972-06-21 1976-03-17 Fujisawa Pharmaceutical Co Chromone derivatives
US3862143A (en) 1972-12-04 1975-01-21 Warner Lambert Co Substituted chromone-3-carbonitriles, carboxamides and carboxylic acids
US3937837A (en) 1972-12-04 1976-02-10 Warner-Lambert Company Substituted chromone-3-carbonitriles, carboxamides and carboxylic acids useful for preventing asthmatic symptoms
DE2731566A1 (de) 1977-07-13 1979-02-01 Bayer Ag Verfahren zur herstellung von neuen chromon-derivaten, sowie ihre verwendung als pflanzenschutzmittel
FR2453170A1 (fr) * 1979-04-06 1980-10-31 Clin Midy Acides 5-(2-hydroxy-3-thiopropoxy)chromone-2-carboxyliques et leurs applications comme medicaments presentant notamment des proprietes antianaphylactiques et antiallergiques
EP0104018A3 (en) * 1982-09-21 1985-06-26 FISONS plc Benzopyran, benzothiapyran and quinoline compounds and pharmaceutical compositions containing them
DE3413007A1 (de) * 1984-04-06 1985-10-17 Audi AG, 8070 Ingolstadt Lenkeinrichtung fuer ein kraftfahrzeug
EP0172352B1 (en) 1984-06-22 1990-08-29 Beecham Group Plc Active benzopyran compounds
GB8515389D0 (en) 1985-06-18 1985-07-17 Ici Plc Heterocyclic compounds
IT1190405B (it) 1985-10-22 1988-02-16 Recordati Chem Pharm Derivati del flavone
US5112856A (en) 1986-08-15 1992-05-12 Hoffmann-La Roche Inc. Therapeutic treatment of intestinal inflammation by administration of 3,4-dihydro-2H-1-benzopyran derivatives
US5387587A (en) 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US5171865A (en) 1988-02-29 1992-12-15 Sanwa Kagaku Kenkyusho Co., Ltd. Process for the preparation of optically active 4-oxo-1-benzopyran-2-carboxylic acid derivatives and intermediates thereof
WO1990012795A1 (en) 1989-04-27 1990-11-01 The Upjohn Company Substituted 3-amino chromans
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5420151A (en) 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
DE4140542A1 (de) 1991-12-09 1993-06-17 Bayer Ag Piperdylmethyl substituierte chormanderivate
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
AU6936194A (en) * 1993-06-10 1995-01-03 Yamanouchi Pharmaceutical Co., Ltd. Novel 8-(2-aminoalkoxy)fluorochroman derivative
JPH11511156A (ja) 1995-08-11 1999-09-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ビフェニル（チオ）アミドおよびビフェニルエタン（チオ）オン誘導体、その製造方法ならびに５−ｈｔ▲下１ｄ▼ 受容体拮抗薬としてのその使用
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
WO1998027080A1 (en) 1996-12-19 1998-06-25 Agrevo Uk Limited Chromones useful as fungicides
JP2001506995A (ja) 1996-12-19 2001-05-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ−ピペラジン−１−イルフェニル−ベンズアミド誘導体
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2199645C (en) * 1997-03-11 1999-06-29 Apotex Inc. Methods for the manufacture of quinolone carboxylic acids derivatives and intermediates thereof
FR2761358B1 (fr) * 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0874043A1 (de) * 1997-04-10 1998-10-28 Preussag AG Verfahren zur Herstellung von Biomasse mittels Photosynthese
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
AU736596B2 (en) * 1997-07-25 2001-08-02 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
SE9703379D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703378D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703377D0 (sv) 1997-09-18 1997-09-18 Astra Ab New compounds
WO1999051401A1 (en) * 1998-04-06 1999-10-14 Acs Industries Inc. Antimicrobial scrub pad
FR2782515B1 (fr) 1998-08-21 2000-09-22 Adir NOUVEAUX DERIVES DE L'INDANE-1-Ol, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
DE60011570T2 (de) * 1999-01-07 2004-11-25 Wyeth Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
AU6866500A (en) 1999-09-01 2001-03-26 Takeda Chemical Industries Ltd. Chromone derivatives, process for the preparation of the same and uses thereof
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
MXPA03006250A (es) 2001-01-16 2003-09-22 Astrazeneca Ab Compuestos heterociclicos terapeuticos.
BR0206513A (pt) 2001-01-16 2004-01-06 Astrazeneca Ab Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds

Also Published As

Publication number Publication date
JP2004517128A (ja) 2004-06-10
NO20033203D0 (no) 2003-07-15
CA2434152A1 (en) 2002-07-18
AR035733A1 (es) 2004-07-07
SA02220710B1 (ar) 2007-01-20
US20050009818A1 (en) 2005-01-13
WO2002055012A2 (en) 2002-07-18
WO2002055012A3 (en) 2002-11-14
KR100864356B1 (ko) 2008-10-17
EP1353913A2 (en) 2003-10-22
JP4280067B2 (ja) 2009-06-17
US20030013708A1 (en) 2003-01-16
US7045514B2 (en) 2006-05-16
KR20030069213A (ko) 2003-08-25
KR20080079341A (ko) 2008-08-29
NZ526697A (en) 2005-05-27
US7285662B2 (en) 2007-10-23
US20050182050A1 (en) 2005-08-18
US6812225B2 (en) 2004-11-02
NZ535574A (en) 2006-07-28
MXPA03006250A (es) 2003-09-22
AU2002217742B2 (en) 2008-02-21
AR068413A2 (es) 2009-11-18
IL156595A0 (en) 2004-01-04
CN100509794C (zh) 2009-07-08
NO20033203L (no) 2003-09-02
CN1527827A (zh) 2004-09-08
US20080076759A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
BR0206513A (pt) Composição, métodos de tratamento de um ser humano ou animal que sofre de depressão, ansiedade generalizada, distúrbios da alimentação, demência, distúrbio do p nico, distúrbios do sono, distúrbios gastrointestinais, distúrbios motores, distúrbios endócrinos, vasoespasmo e disfunção sexual, uso de qualquer um dos compostos, composição farmacêutica, e, processo para preparar compostos
BR0213778A (pt) Composição, método de tratamento de um ser humano ou animal que sofre de doenças, e, uso da composição
BR0213748A (pt) Compostos, método de tratamento de um ser humano ou um animal e uso de qualquer um dos compostos
BR0213838A (pt) Compostos, método de tratamento de um humano ou animal, e, uso de qualquer um os compostos
WO2002055012A3 (en) Therapeutic heterocyclic compounds
ES2168006T3 (es) Factor neurotrofico ciliar modificado, metodo de fabricacion y metodos de utilizacion.
NZ332802A (en) Aryl pyrimidine and their use in treating nervous disorders
DE3576331D1 (de) Tetralin-derivate, ihre herstellung und verwendung.
ES2248356T3 (es) Compuestos para tratar la enfermedad de alzheimer.
GEP20074171B (en) N,n'−substituted−1,3−diamino−2−hydroxypropane derivatives
BR9606755A (pt) Novos compostos de aminopiridina policíclica os quais são inibidores da aceticolinesterase processo para a sua preparação e seu uso
WO2002002520A3 (en) Compounds to treat alzheimer's disease
BR0206514A (pt) Composto, método de tratamento de um ser humano ou animal que sofre de enxaqueca, uso do composto, composição farmacêutica, e, processo para preparar um composto
DK1109817T3 (da) Phosphohalogenhydriner, deres fremstilling og anvendelse
PT902022E (pt) Novos derivados de benzofuranona e processo para a sua producao
AU5614198A (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
EP1114809A4 (en) Process for the preparation of fluorobenzyl derivatives
BR0209342A (pt) Antidepressivos de azaheterociclilmetila derivados de 2,3 dihidro-1,4-dioxino[2,3-f]quinoxalina; método de tratamento usando tais compostos; processo para prepará-los
DE60216776D1 (de) Neue piperidin-2,6-dion bisulfatsalze und deren verwendung für die behandlung stressbezogener gemütserkrankungen
ITMI20011205A0 (it) Processo integrato di produzione di 2,6 dimetilfaftalene
BR9407271A (pt) Beta-aminovinilcetonas processo de preparação e utilização das mesmas
ATE221070T1 (de) Verfahren zur herstelung von pirlindolehydrochlorid
GB0219639D0 (en) Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
SE0103647D0 (sv) Therapeutic chromone compounds
HUP0400173A3 (en) Method for producing an essentially chlorite-free stable aqueous chlorine-oxigen solution the chlorine-oxigen solution obtained by means of said method and the use of the same

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.